Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exco InTouch Joins C-Path ePRO Consortium

Published: Tuesday, May 21, 2013
Last Updated: Tuesday, May 21, 2013
Bookmark and Share
Company joins ePRO Consortium to advance electronic data capture in clinical trials.

Exco InTouch has announced that it has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a programme run by the Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals.

The ePRO Consortium is committed to improving the quality, practicality and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment.

As PRO endpoints have become increasingly common in studies for evaluating patients’ perspectives of a particular drug, the requirement for better measures of patients’ experiences has become even more critical.

Exco InTouch will work closely with other Consortium members from a number of industry-leading providers of innovative electronic data collection technologies, to develop guidelines for the adaptation of PRO measures to the appropriate ePRO solutions.

The ePRO Consortium will generate measurement equivalence data, develop specification documents and data standards, and produce methodological guidance on measurement issues related to ePRO applications.

The association will also work closely with C-Path’s PRO Consortium, a group of 25 pharmaceutical companies working to develop novel PRO measures, with the goal of making these new measures available for electronic data capture formats.

The aim of the programme is to enhance public health by optimizing the value of PRO data in medical product evaluation and clinical decision making.

“Exco InTouch is delighted to join the ePRO Consortium to help advance the science of electronic data capture and create standardized guidelines to ensure all data collated electronically in clinical trials is valid and reliable,” comments Tim Davis, CEO of Exco InTouch.

Davis continued, “The Consortium provides a neutral and collaborative environment for the industry to work together to develop and advocate consistent approaches for drug development.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exco InTouch Granted United States Patent for mDNA® Technology
An automated management tool that identifies, distributes and manages patients and their mobile device.
Thursday, July 23, 2015
Exco InTouch Unveils Comprehensive White Paper on Effective Mobile Strategies
The company, together with leading academic experts, has produced a highly definitive guide for the industry.
Thursday, June 04, 2015
Exco InTouch Shortlisted for the Best Technological Development in Clinical Trials 2014 SCRIP Award
Selection for the accolade shortlist recognizes the company’s mDNA® technology project team - leading the way with innovation in the field of patient engagement and data capture solutions to enhance efficiencies in clinical trials.
Wednesday, October 08, 2014
Exco InTouch Shortlisted for the Best Technological Development in Clinical Trials 2014 SCRIP Award
Selection for the accolade shortlist recognizes the company’s mDNA® technology project team - leading the way with innovation in the field of patient engagement and data capture solutions to enhance efficiencies in clinical trials.
Saturday, October 04, 2014
Pharma Industry Encouraged to Adopt Mobile ePRO for Clinical Trials Efficiency at DIA 2014
Exco InTouch outlines strategies to introduce mobile solutions into clinical trials at DIA Annual Meeting.
Friday, June 06, 2014
Exco InTouch Unveils Exco™ Valued Partner Network
Innovative partner network to facilitate integration of digital patient engagement and data capture in clinical research programs.
Friday, March 28, 2014
Laurence Burke Joins Exco InTouch as Vice President of Operations
Position set to ensure provision of robust, streamlined and efficient patient engagement and data capture programs applied across clinical, late phase and mHealth sectors.
Thursday, February 20, 2014
Exco InTouch Successfully Completes HIPAA Security Audit
Audit to assess compliance utilizing the NIST guidelines for HIPAA security.
Wednesday, January 22, 2014
Exco InTouch Continues Significant Growth with Appointment of CTO
Appointment of Madhav Vattikuti as chief technology officer.
Thursday, February 02, 2012
Exco InTouch Wins EOA for Second Year Running
Company wins ‘Best eBusiness/IT Strategy’ award at European Outsourcing Awards 2011.
Friday, November 04, 2011
Exco Intouch Secures Growth Investment from SEP
Mobile patient communication leader to use funds to accelerate growth strategy.
Tuesday, October 04, 2011
Exco InTouch Receives ePRO Accolade at the 2010 European Outsourcing Awards
Exco InTouch has been recognised for its delivery of electronic Patient Reported Outcomes (ePRO) solutions at the 2010 European Outsourcing Awards. The award for Most Innovative Relationship was in recognition of their collaborative study with The University of Queensland.
Thursday, November 25, 2010
mobilePRO Solution for Patient Data Capture by Exco InTouch
New mobilePRO technology is a powerful solution that overcomes issues associated with traditional ePRO.
Monday, August 23, 2010
Exco InTouch Opens New Global Headquarters
Exco InTouch, a provider of patient communication solutions for the pharmaceutical and healthcare sectors, announced today that it has opened a new global headquarters at Pishiobury House, Hertfordshire, UK.
Thursday, October 22, 2009
Exco InTouch’s ePRO Technology Improves Patient Compliance by up to 95%
Exco InTouch, the leading provider of patient communication solutions for the pharmaceutical and healthcare sectors, announces that its secure mobile data capture platform, REACT CELL™, significantly improves patient retention and compliance in clinical studies.
Tuesday, August 18, 2009
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!